Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00458601 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT00458601
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00458601 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Lead sponsor
Celldex Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2007
Completion date
May 31, 2016
Enrollment
82 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

malignant glioma